SEARCHNARRATIVE_REVIEWhematology, oncology

narrative_review·hematology, oncology, immunology, gastroenterology, biomedical research·PMC10312041

Fecal microbiota transplantation in hematopoietic cell transplant and cellular therapy recipients: lessons learned and the path forward

Gut Microbes · 2 authors, 2 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

It highlights a randomized controlled trial showing prophylactic FMT after transplant did not significantly reduce infection rates.

Full summary

189 CHARS

The primary outcome was the 4-month all-cause infection rate, which was numerically lower with FMT but not statistically significant (P=0.49). Acute GVHD incidence was a secondary endpoint.

STUDY TYPE

narrative_review

SPECIALTY

hematology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10312041

Fecal microbiota transplantation in hematopoietic cell transplant and cellular therapy recipients: lessons learned and the path forward

Gut Microbes

READ THE FULL PAPER

ABSTRACT

ABSTRACT Disruptions to the gut microbiota have been associated with adverse outcomes including graft-versus-host disease, infections, and mortality after hematopoietic cell transplantation and cellular therapy. Evidence for causal links is accumulating, thus supporting therapeutic interventions targeting the microbiota with the goal of preventing and treating adverse outcomes. One such intervention is fecal microbiota transplantation (FMT) by which an entire community of gut microbiota is transferred to the patient with dysbiosis. As this approach in transplant and cellular therapy recipients is still in its infancy, no best approach has been defined and many open questions need to be addressed before FMT becomes a standard treatment. In this review, we highlight microbiota-outcome associations with the highest level of evidence, provide an overview of the main FMT trials, and suggest some paths forward. KEYWORDS: Cellular therapy, Dysbiosis, Fecal microbiota transplantation, Graft-versus-host disease, Hematopoietic cell transplantation, Microbiota

CITATION EXPORT

Shaghayegh Habibi, Armin Rashidi. Fecal microbiota transplantation in hematopoietic cell transplant and cellular therapy recipients: lessons learned and the path forward. Gut Microbes. (2023). https://doi.org/10.1080/19490976.2023.2229567

AUTHORS

2 · 2 CENTRES

Shaghayegh Habibi, Armin Rashidi

aLucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA
bClinical Research Division, Fred Hutchinson Cancer Center; and Division of Oncology, University of Washington, Seattle, WA, USA